[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type1-diabetes-mellitus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type1-diabetes-mellitus":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,78,103,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100335553","genetics-of-autoimmunity-in-type-i-diabetes-100335553",false,"NCT03648918","Genetics Of Autoimmunity In Type I Diabetes","Inclusion Criteria (Families):\n\n* Families where at least one first-degree family member has type 1 diabetes\n* The diabetic proband in the family was diagnosed before the age of 39\n* Family members must be at least 2 years old to participate\n\nExclusion Criteria (Families):\n\n* Families with no history of type 1 diabetes\n* Families with a history of diabetes that is not type 1 (LADA, MODY, type 2 etc.)\n\nInclusion Criteria (Controls):\n\n* No family history of type 1 diabetes or other autoimmune conditions\n* Age 2 or older\n\nExclusion Criteria (Controls):\n\n* Personal or family history of autoimmune disease",true,"ALL","2 Years",{"count":19,"type":20},4000,"ESTIMATED","10 Years","OBSERVATIONAL","The purpose of this study is to gain more information about the step-by-step process that causes someone to develop type 1 diabetes. Scientists think that a person's own immune system, directed by genetic and environmental factors play a major role in its development. Participation involves a blood draw, a brief medical history questionnaire and measurements of height and weight. Some participants will be asked to return for annual follow-up visits for 10 years.",[25,26,27,28],"Type1diabetes","Diabetes Mellitus, Type 1","Type1 Diabetes Mellitus","Diabetes Mellitus",[30,31,32],"Family","Healthy Controls","Siblings","RECRUITING","2026-03-12",{"date":36,"type":37},"2026-03-16","ACTUAL",{"date":39,"type":37},"2001-08",{"date":41,"type":20},"2050-01",{"name":43,"class":44},"Medical College of Wisconsin","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100314156","extremely-early-onset-type-1-diabetes-extremely-early-onset-type-1-diabetes-a-musketeers-memorandum-study-100314156","NCT03369821","EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)","Understanding Beta-cell Destruction Through the Study of EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)","EXE-T1D","Inclusion Criteria:\n\nStudy 1:\n\nEET1D\n\n* Aged 0 to 70 years\n* Clinical diagnosis of diabetes \\\u003C24 months (+ evidence of WHO diabetes criteria)\n* Negative genetic test for mutations causing non-autoimmune neonatal diabetes if diagnosed \\\u003C12 months\n* Type 1 diabetes genetic risk score \\>50th centile of T1D reference group, or monogenic cause of T1D.\n\nT1D Controls\n\n* Age 0-70 years (matched to above)\n* Clinical diagnosis of T1D (diagnosed age 1-20 years)\n* Insulin treated from diagnosis.\n\nMonogenic \u002F NDM controls\n\n* Diagnosis of diabetes \\\u003C12 months\n* Diagnosis of monogenic \u002F NDM (confirmed by Exeter Molecular Genetics Laboratory).\n\nStudy 2:\n\nEET1D\n\n* Aged 0 to 24 months at recruitment\n* Clinical diagnosis of diabetes \\\u003C24 months (+ evidence of WHO diabetes criteria)\n* Negative genetic test for mutations causing non-autoimmune neonatal diabetes\n* Type 1 diabetes genetic risk score \\>50th centile of T1D reference group, or monogenic cause of T1D.\n\nMonogenic\u002FNDM controls\n\n* Diagnosis of diabetes \\\u003C24 months\n* Age 0 to 18 months at recruitment\n* Diagnosis of monogenic\u002FNDM (confirmed by Exeter Molecular Genetics Laboratory).\n\nNon-diabetic controls\n\n* Aged 0-6 years\n* Attending specified participating hospital sites for elective surgery, including but not limited to: inguinal hernia repair, umbilical\u002Fmidline hernia repair, orchidopexy, gastrostomy insertion\u002Fchange, hypospadias repair, cleft palate repair, excision of accessory digit, laryngoscopy, adenoidectomy, tonsillectomy, MRI under general anaesthesia, eye surgery.\n\nExclusion Criteria:\n\nStudy 1:\n\n* Aged \\>70 years\n* No diagnosis of diabetes\n* MODY (e.g. caused by HNF1A\u002FHNF4A\u002FHNF1B\u002FGCK mutations), type 2 diabetes or diabetes related to pancreatic insufficiency or syndromic diabetes\n* Intercurrent illness at time of sampling for PBMCs (see below).\n\nStudy 2:\n\n* Aged \\>24 months\n* Clinical diagnosis of diabetes \\>24 months\n* Intercurrent illness at time of sampling for PBMCs or RNA (see below).\n\nNon-diabetic controls:\n\n* Aged \\>6 years\n* Diagnosis of diabetes or other autoimmune condition\n* Known immunological disorder\n* On immunosuppressive medication\n* Ongoing infections\u002Fsepsis\n* Major congenital abnormality or significant systemic illness that may affect the immune system, e.g. metabolic disease, 22q deletion syndrome\n* Recent (within two weeks) febrile illness\n* Renal failure.\n\nFor PBMC and RNA sampling: Exclusion for factors that may alter T cell function and RNAseq\n\nReview the following exclusion criteria carefully at time of appointment as some details may have changed since initial contact:\n\n* Recreational drug use (excluding cannabis use more than 1 week prior to blood sampling) - drug abuse may alter T cell function\n* Alcohol related illness (excessive alcohol consumption may alter T cell function)\n* Renal failure: Creatinine \\>200 (as may alter T cell function)\n* Any other medical condition which, in the opinion of the investigator, would affect the safety of the subject's participation.\n\nFactors that if temporary would lead to rearrangement of study visit but if long duration, may lead to exclusion subject to the CI's discretion:\n\n* Pregnant or lactating (as this may limit blood sampling and affect T cell function)\n* Any infectious illness within the last 2 weeks if it was a febrile illness, or within 2-3 days if it was non-febrile (as this may activate T cells non-specifically)\n* Taking steroids or other immunosuppressive medications (as these may alter T cell function)\n* Received any immunoglobulin treatments or blood products in the last 3 months (as these may alter T cell function).","70 Years",{"count":56,"type":20},300,"Type 1 diabetes (T1D) results from destruction of insulin-producing beta cells in the pancreas by the body's own immune system (autoimmunity). It is not fully understood what causes this type of diabetes and why there is variation in age of onset and severity between people who develop the disease. The aim of this work is to study very unusual people who develop T1D extremely young, as babies under 2 years of age (EET1D). The investigators think that, for the condition to have developed that early, they must have an unusual or extreme form of autoimmunity.\n\nStudying people with EET1D will enable us to look at exactly what goes wrong with the immune system because they have one of the most extreme forms of the disease. Much may be learned about the disease from a small number of rare individuals. The investigators aim to confirm that they have autoimmune type 1 diabetes and then try to understand how they have developed diabetes so young by studying their immune system genes, the function of their immune system, and environmental factors (such as maternal genetics) that may play a role in their development of the disease.\n\nPeople with diabetes diagnosed under 12 months are very rare, live all over the world. and are usually referred to Exeter for genetic testing. Individuals will be contacted via their clinician to ask for more information about their diabetes and their family history. Samples will be collected to study whether they still make any of their own insulin and whether they make specific antibodies against their beta cells in the pancreas. Separately, their immune system will be studied in depth using immune cells isolated from a blood sample. These cells will undergo cutting edge techniques by Dr Tim Tree at King's College London, by Professor Bart Roep at Leiden University Medical Center, Netherlands, and Dr Cate Speake, Benaroya Research Institute, Seattle (USA). Some of these tests have never been used in people of young ages around the world, so an aim of this project will be to develop methods that can be used to study people even if they live far away.\n\nAdditional funding extended the study for a further 3 years (Phase 2) to include recruitment of infants without diabetes, aged 0-6 years, as controls to enable assessment of how the abnormalities found in autoimmune and non-autoimmune diabetes compare to normal early life development of the immune system.\n\nAn additional funding award extended the study (Phase 3) until November 2028, to advance the EXE-T1D program into its third phase, building on major discoveries from phases 1 and 2 to identify, validate, and target immune pathways that drive extremely early-onset type 1 diabetes (eeT1D) and are likely relevant to T1D across all ages. eeT1D cases, diagnosed within the first two years of life, represent particularly aggressive onset of beta-cell autoimmunity. They offer a unique lens to uncover mechanisms of immune dysregulation, informed by both polygenic and monogenic causes. The central aim is to move from pathway discovery to demonstration of novel druggable targets with potential to delay or prevent T1D onset across all ages.",[27],[60,61,62,63,64,65,66,67],"type 1 diabetes","monogenic diabetes","autoimmune diabetes","early-onset autoimmune diabetes","beta cell (β-cell) destruction","type 1 diabetes genetic risk","extremely early-onset Type 1 diabetes","neonatal diabetes","2025-12-12",{"date":70,"type":37},"2025-12-19",{"date":72,"type":37},"2017-09-19",{"date":74,"type":20},"2028-11-30",{"name":76,"class":44},"University of Exeter",4,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100498982","continuous-monitoring-of-glycemic-variability-to-predict-dys--and-hyperglycemia-in-asymptomatic-type-1-diabetes-100498982","NCT05777330","Continuous Monitoring of Glycemic Variability to Predict Dys- and Hyperglycemia in Asymptomatic Type 1 Diabetes","Inclusion Criteria:\n\n1. aged 5-39 years at inclusion;\n2. absence of diabetes meeting the clinical diagnostic American Diabetes Association (ADA) criteria;\n3. persistently positive for one or multiple types of autoantibodies among IAA, GADA, IA-2A and ZnT8A.\n\nExclusion Criteria:\n\n1. Pregnancy or lactation in women; \\\u003C6 months postpartum\n2. Diabetes meeting the clinical diagnostic ADA criteria;\n3. Use of illicit drugs, or overconsumption of alcohol, or history of drug or alcohol abuse;\n4. Being legally incapacitated, having significant emotional problems at the time of the study, or having a history of psychiatric disorders;\n5. Treatment with immune modulating or diabetogenic medication (e.g. corticosteroids) or medication that act to lower glycemia (oral antidiabetics) or agents that may influence insulin sensitivity or secretion;\n6. Gastric bypass or banding;\n7. History of acute or chronic pancreatitis, or (partial) pancreatectomy\n8. History of any illness that, in the opinion of the investigator, might confound the results of the study or pose additional risks to the subjects.","5 Years","39 Years",{"count":87,"type":20},75,"INTERVENTIONAL",[90],"NA","The goal of this longitudinal clinical trial is to measure variability of interstitial glucose levels with a user-friendly real-time continuous glucose monitoring (CGM) technology at regular intervals in normo- and dysglycemic multiple autoantibody-positive individuals (age 5-39 years), in comparison with single autoantibody-positive individuals in the same age range. Participants will asked to undergo repeated oral glucose tolerance tests (OGTTs) (age 5-39 years) and hyperglycemic clamp tests (age 12-39 years) in parallel for a period of at least 2-3 years. In case of confirmed dysglycemia, we propose to perform CGM and OGTT every 3 months.\n\nThe main questions the study aims to answer are:\n\n1. Do the amplitude and time trends of CGM-derived glycemic variability indices and OGTT- and clamp-derived variables differ between the intermediate, high and very high risk groups?\n2. Can (changes in) CGM-derived glycemic variability indices predict\u002Fdetect dysglycemia in initially normoglycemic (single or multiple autoantibody-positive) individuals with the same diagnostic efficiency as OGTT- or clamp-derived variables?\n3. Can (changes in) CGM-derived glycemic variability indices predict clinical onset in (stage 1 or 2) multiple autoantibody-positive individuals with the same diagnostic efficiency as OGTT- or clamp-derived variables?\n4. Can correlating (changes in) CGM-derived indices with (changes in) OGTT- and clamp-derived variables help to better understand the sequence of events leading to dysglycemia and clinical onset, as well as the relative contribution of beta cell function and insulin action to glycemic variability according to disease stage and biological and phenotypical characteristics of the individuals?",[27],"2025-08-25",{"date":95,"type":37},"2025-09-02",{"date":97,"type":37},"2023-08-09",{"date":99,"type":20},"2028-08",{"name":101,"class":44},"Universitair Ziekenhuis Brussel",6,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":114,"studyType":22,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":45},"100348030","china-diabetes-registry-by-metabolic-management-center-100348030","NCT03811470","China Diabetes Registry by Metabolic Management Center","China Diabetes Registry - a Prospective Cohort Study of Patients With Diabetes in National Metabolic Management Centers in China","CDR-MMC","Main Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Diagnosis of diabetes mellitus based on self-reported history of diagnosed diabetes by clinicians or in line with the current domestic diagnostic criteria for diabetes\n* Gender: males and females\n* Provide written informed consent\n* Satisfactory compliance\n\nMain Exclusion Criteria:\n\n* Patients with significantly reduced life expectancy (less than 5 years)\n* With Drug abuse\n* With AIDS or syphilis or infectious diseases such as viral hepatitis or tuberculosis in active phase at enrollment","18 Years",{"count":113,"type":20},1000000,"20 Years","Epidemiologic studies have revealed a tremendous increase in the prevalence of diabetes and related mortality worldwide. In order to meet all the challenges in the treatment of metabolic diseases in China, the National Metabolic Management Center (MMC) was founded in 2016. The objective of the MMC is to launch a new metabolic disease management model based on the Internet health information platform. It allows the application and evaluation of diabetes treatment strategies at these centers. The proprietary electronic medical database in the MMC will help the dynamic big-data analysis in diabetes epidemiology, prevention, diagnosis, and treatment. It will also provide prospective data support including economic evaluation in management of chronic diseases for the Healthy China 2030 strategy.\n\nObjective\n\n1. The purpose of the present study is to establish a multi-center nationwide prospective database of diabetes patients in MMCs, including clinical data, biological samples library so as to explore the epidemiology, genetics, new biomarkers, risk factors, and prognostic methods related to diabetes and its complications, as well as other metabolic diseases.\n2. To collect cross-sectional data from patients seen and treated at each MMC centers so as to evaluate: the current status of care of patients with diabetes and its related complications, as well as other risk factors treatment strategies at these centers. Patients'costs and quality of life (QoL) will also be evaluated.\n3. To collect the prospective data of patients treated at each MMC centers in order to evaluate the strategies for the achievement of treatment goals, changes in management, control of risk factors, incidence and progression of all-diabetes related clinical endpoints (including mortality), behavioral changes, psychological well being as well as costs and QoL.",[117,27,118,119,120,121],"Type 2 Diabetes Mellitus","Monogenetic Diabetes","Pancreatogenic Diabetes","Drug-Induced Diabetes Mellitus","Other Forms of Diabetes Mellitus","2024-12-02",{"date":124,"type":37},"2024-12-05",{"date":126,"type":37},"2017-05-31",{"date":128,"type":20},"2039-05-31",{"name":130,"class":44},"Guang Ning",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":155},"100562695","the-survey-of-treatment-and-metabolic-status-of-type-1-diabetes-mellitus-t1dm-100562695","NCT06606509","The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).","The Chinese Clinical Research Plan for the Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).","Inclusion Criteria:\n\n* Volunteer to participate and be able to sign informed consent\n* Patients with type 1 diabetes\n* At least one of the following three clinical characteristics must be met: The disease presents initially with diabetic ketoacidosis (DKA) or ketonuria; The presence of islet-related autoantibodies, such as islet cell antibodies, tyrosine phosphatase antibodies, or glutamic acid decarboxylase (GAD) antibodies, is detected positively; Both fasting and postprandial C-peptide levels are ≤0.6 ng\u002FmL.\n\nExclusion Criteria:\n\n* Other types of diabetes.\n* Patients who cannot cooperate with the use of continuous glucose monitoring, clinical data collection, and questionnaire completion.",{"count":139,"type":20},1000,"This study is a multicenter cross-sectional research project, planning to enroll 1000 patients with Type 1 Diabetes Mellitus (T1DM). By reviewing clinical data, physical examinations, questionnaires, continuous glucose monitoring, and subcutaneous fat ultrasound, we aim to understand the current status of treatment and metabolism in Chinese T1DM patients and analyze the potential factors that may affect their blood sugar control and metabolic indicators. A cost-effectiveness analysis will be conducted on Chinese T1DM patients using continuous glucose monitoring systems to identify the groups that benefit most from these systems.",[27],[143,144],"Continuous Glucose Monitoring (CGN)","Glucose fluctuations","NOT_YET_RECRUITING","2024-09-18",{"date":148,"type":37},"2024-09-23",{"date":150,"type":20},"2024-11-07",{"date":152,"type":20},"2027-06-30",{"name":154,"class":44},"Nanjing First Hospital, Nanjing Medical University",101]